Belvedere Trading’s Atossa Therapeutics ATOS Stock Holding History

Belvedere Trading’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-127	Closed	-$1K	–	931
2022 Q4	$1K	Buy	+127	New	+$1.46K	﹤0.01%	1074

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Belvedere Trading's ATOS Position: Q1 2023 in Review

Belvedere Trading sold out of Atossa Therapeutics (ATOS) in Q1 2023, closing a stake of 33 shares — an estimated $265 sold.

Belvedere Trading first reported a position in ATOS in Q4 2021 and held it in 2 quarters. The position peaked at $15K in Q4 2021. 45 funds tracked by Wall St. Rank hold ATOS as of Q1 2023.

Belvedere Trading reported no remaining Atossa Therapeutics position as of Q1 2023 after selling out during the quarter.
Belvedere Trading sold 33 Atossa Therapeutics shares in Q1 2023, an estimated $265.
Belvedere Trading first reported a position in Atossa Therapeutics in Q4 2021 and held it in 2 quarters.
Belvedere Trading's Atossa Therapeutics position peaked at $15K in Q4 2021.
45 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.